Skip to main content
Martínez de Castro on Muck Rack

Martínez de Castro

As seen in: Nature, Dialnet - Universidad de La Rioja
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Martínez

Contact Martínez, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

El trastorno del espectro autista como base de un problema de alimentación. Una visión desde el cuidado enfermero: Informe de caso

|
By Ana Saiz, Martínez de Castro, Cobo Sánchez, Bermúdez Saiz
| Dialnet - Universidad de La Rioja
Ayuda Buscar en la ayuda Buscar en la ayuda El trastorno del espectro autista como base de un problema de alimentación.
Open in Who Shared Issue with article?

Comisión Provincial de Monumentos Históricos y Artísticos de Almería

|
By Martínez de Castro
| Dialnet - Universidad de La Rioja
Ayuda Buscar en la ayuda Buscar en la ayuda
Open in Who Shared View Duplicates (535) Issue with article?

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial - British Journal of Cancer

|
By María Auxiliadora, Maria Jose, Inmaculada Alés, Martínez de Castro
| Nature Verified
Abstract Background Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE). Methods Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI.
Open in Who Shared Issue with article?
See all 3 articles